. "Investigated for use/treatment in arrhythmia and atrial fibrillation."@en . . . " "@en . . . . . . . . . . . . . . "Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. It is being developed by CV Therapeutics, Inc."@en . . . . . "Tecadenoson"@en . . . . . . . . "Humans and other mammals"@en . "# Peterman C, Sanoski CA: Tecadenoson: a novel, selective A1 adenosine receptor agonist. Cardiol Rev. 2005 Nov-Dec;13(6):315-21. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16230891"@en . "investigational"@en . . "204512-90-3"@en . "Tecadenoson selectively stimulates the A1 adenosine receptor. Stimulation of the A1 adenosine receptor slows the conduction of electrical impulses in the AV node of the heart, a region that controls the transmission of electrical impulses from the atria to the ventricles."@en . . . . .